PRESS RELEASE published on 01/30/2024 at 06:00, 2 years 4 months ago Sales at prior-year level with decline in market momentum
PRESS RELEASE published on 10/26/2023 at 06:00, 2 years 8 months ago Increase in sales despite a slowdown in business momentum
PRESS RELEASE published on 07/27/2023 at 06:00, 2 years 10 months ago Further increase in sales and significant rise in operating profit
PRESS RELEASE published on 04/27/2023 at 06:00, 3 years 1 month ago Sales grow markedly, demand remains at a high level
PRESS RELEASE published on 04/19/2023 at 18:10, 3 years 2 months ago Annual general meeting 2023: all proposals of the board of directors approved
PRESS RELEASE published on 01/26/2023 at 06:00, 3 years 5 months ago Pleasing performance in a challenging environment
Published on 06/26/2026 at 14:05, 1 hour 58 minutes ago SouthGobi Announces Voting Results of Annual General Meeting of Shareholders
Published on 06/26/2026 at 14:00, 2 hours 3 minutes ago Dateline Chairman Invests $1.95 million through Options Exercise
Published on 06/26/2026 at 13:00, 3 hours 3 minutes ago Aclara Secures Tax Exemption Approval of Over US$20 Million For Its U.S. Heavy Rare Earth Separation Facility in Louisiana
Published on 06/26/2026 at 12:45, 3 hours 18 minutes ago Northern Dynasty Reports Oral Arguments Held
Published on 06/26/2026 at 15:30, 33 minutes ago JMGO Extends Special Savings Beyond Prime Day with N3 Ultimate at Its Best Price Since Launch
Published on 06/26/2026 at 15:23, 39 minutes ago Form 8.3 - The Vanguard Group, Inc.: Tate & Lyle plc
Published on 06/26/2026 at 15:23, 40 minutes ago Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group plc
Published on 06/26/2026 at 07:00, 9 hours 3 minutes ago Advancing Women’s Health with Rapid Diagnostics: bioMérieux files a Dual 510(k) /CLIA Waiver application to the FDA for the BIOFIRE® SPOTFIRE® Vaginitis Panel
Published on 06/26/2026 at 07:00, 9 hours 3 minutes ago Améliorer la santé des femmes grâce au diagnostic rapide : bioMérieux dépose auprès de la FDA une demande combinée d’autorisation 510(k) et de dérogation CLIA pour son test BIOFIRE® SPOTFIRE® Vaginitis Panel